Hallway Conversation: Perampanel

Published Online: Tuesday, March 20, 2012
In this podcast, part of Epilepsy.com’s Hallway Conversations series, Joseph Sirven, MD, professor of neurology at Mayo Clinic Arizona and editor-in-chief of Epilepsy.com, interviews Gregory Krauss, MD, professor of neurology at Johns Hopkins Medical School, about the promising new antiepileptic drug (AED) perampanel.
 
Dr. Krauss explains that perampanel, the first drug in its class fully developed to treat epilepsy, targets the AMPA receptor, 1 of 3 receptors that help control neuronal excitability of the sort involved in seizure generation. He adds that the drug has a long half life of 70 hours, which means that it only has to be taken once a day. In addition, he notes that perampanel, which has not yet been approved by the FDA, has shown great promise in treating refractory epilepsy, although there have been some variations in trial results, particularly from centers where data may not have been accurately recorded.
 
To listen to the podcast, click here and scroll down to the October 24, 2011, episode.
Latest Articles
This weekly video program provides our readers with an in-depth review of the latest news, product approvals, FDA rulings and more.
Chronic kidney disease incidence has grown faster than many of its common comorbidities such as diabetes and hypertension, and medications may be an underappreciated driver of this growth.
President Barack Obama’s fiscal year 2017 budget proposal calls for an additional $1.1 billion to combat the nation’s spiraling opioid epidemic.
Baxter International is voluntarily recalling intravenous solution due to leaking containers and the potential for particulate matter.
Latest Issues
$auto_registration$